Medicare AdvantageAdministrativeLow impact
MA08.145a, Sutimlimab-jome (Enjaymo)
Independence Blue Cross·NJ · Hematology, Pharmacy·Pharmacy
We identified it
Jun 19, 2026
Summary
Independence Blue Cross reissued MA08.145a on 07/22/2026 to communicate the Company's continuing position on sutimlimab-jome (Enjaymo) for cold agglutinin disease treatment. No substantive coverage changes have been made; this is a routine policy reaffirmation with the same medical necessity criteria, HCPCS code (J1302), and dosing guidelines remaining in effect.
Action Required
No immediate action required. This is a reissue with no changes to coverage policy, billing codes, or medical necessity criteria. Billing team should maintain current processing procedures for Enjaymo claims under HCPCS code J1302. Continue verifying that member documentation meets all stated medical necessity criteria (CAD diagnosis confirmation, lab values, transfusion history, weight, infection status, and vaccination status) before claim submission.